GlobeNewswire by notified

Aduro and Prospera Enter into LOI to Collaborate on Pilot Plant for Partial Upgrading of Bitumen

Share

SARNIA, Ontario, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics and transform heavy crude and renewable oils into new-era resources and higher-value fuels, is pleased to announce that, through its wholly-owned subsidiary, Aduro Energy Inc., it has entered into a Letter of Intent (“LOI”) dated September 12th, 2022 with Prospera Energy Inc. (“Prospera”) with the purpose of developing, building, and supplying a pre-commercial pilot plant to convert low API bitumen to higher value products.

To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

Prospera Energy Inc. (TSX.V: PEI, OTC: GXRFF, FRA: OF6B) is an operator in Canada's energy industry offering exposure to exploration, development, and production of crude oil and natural gas. Prospera is engaged in the acquisition, development, and production of crude oil and natural gas in Western Canada. Its core assets are medium to heavy oil properties (12-17 API) located along the Alberta-Saskatchewan border of Cuthbert, Heart Hills, and Luseland.

On September 7, 2022 Aduro announced that its scaled-up continuous flow bitumen reactor was nearing completion and readiness for customer trials and engagement acceleration. This LOI is the Company’s second engagement on the bitumen vertical with a producer in Alberta.

The LOI outlines an 18-month plan with three phases. Phase one, which will commence during the month of October, includes the testing of bitumen feedstocks and the evaluation of the economics. It is expected to be completed in Q1 2023. Phase two includes preliminary engineering, identification of the pilot plant site, and reviewing of licenses and permits, as well as detailed budgeting and agreement to proceed with construction. Phase two is scheduled for completion in Q3 2023. Phase three includes the procurement, fabrication, construction, commissioning, and operation of a 50 bbl/day pilot plant. Work is expected to be completed in Q2 2024. After completion of phase three, Aduro and Prospera will define a roadmap to commissioning a 3,000 bbl/day commercial facility.

In consideration for the services to be provided in phase one, Prospera will pay Aduro a monthly fee of $25,000CAD plus applicable taxes, with the total fees for the completion and delivery of phase one scope capped at $125,000 plus applicable taxes.

“Prospera Energy is primarily focused on optimizing hydrocarbon recovery through environmentally safe and efficient development and production practices,” according to Samuel David, President & CEO of Prospera. “We are investing in innovation that reduces blend down stock, improves the product specification, increases unit economics, and has a lower carbon footprint. We are motivated by the potential impact that this technology can have on our operations.”

“Aduro’s research and engineering team has been building the necessary tools to enable Aduro to test an expanded range of customer feedstock, and we are very excited to apply it to Prospera’s crude and to demonstrate our ability to unlock the value of lower API bitumen,” says Ofer Vicus, Chief Executive Officer at Aduro. “By partnering with Samuel David and the Prospera team, we will have access to resources and support in building and operating a pilot plant facility, an important milestone on our path to commercialization.”

About Prospera Energy
Prospera Energy Inc. is a public oil and gas exploration, exploitation, and development company focusing on conventional oil and gas reservoirs in Western Canada. Prospera uses its experience to develop, acquire, and drill assets with potential for primary and secondary recovery.

About Aduro Clean Technologies 
Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company’s Hydrochemolytic™ technology activates unique properties of water in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into 21st-century resources.

For further information, please contact:

Ofer Vicus, CEO
ovicus@adurocleantech.com

Samuel David, President & CEO
sam@prosperaenergy.com

Abe Dyck
ir@adurocleantech.com
+1 604-362-7011

Investor Cubed Inc.
Neil Simon, CEO
nsimon@investor3.ca
+ 1 647 258 3310

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events, or developments that the Company believes, expects or anticipates will or may occur in the future, are forward-looking statements. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements. Forward-looking statements in this news release include: the completion of the LOI by all parties, including the work to be completed and the payment of anticipated compensation; the anticipated benefits to the Company of the LOI, including recognition of Aduro’s technology as a leading-edge cleantech solution, expansion of Aduro’s presence in its sector, the access to resources to assist in building and operating a pilot plant facility and the LOI serving as an important milestone in the Company’s path to commercialization. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Important factors that could cause actual results to differ materially from the Company’s expectations include, but are not limited to, the following: the LOI may not be completed, for various reasons, as anticipated or at all; the anticipated benefits of the LOI may not occur as expected or at all, including that the LOI may not increase recognition of Aduro’s technology as a leading-edge cleantech solution, result in expansion of Aduro’s presence in its sector, increase access to resources to assist in building and operating a pilot plant facility, or serve as a an important milestone in the Company’s path to commercialization; the Company may be unable to achieve commercialization of its technology or business as anticipated or at all; adverse market conditions and other factors beyond the control of the parties may negatively impact the business and operations of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

The CSE has not reviewed, approved, or disapproved the content of this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/262678fc-f932-41f6-b8bf-9f172b7e1cd2

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Schouw & Co. aktietilbagekøbsprogram, uge 18 20246.5.2024 15:11:08 CEST | pressemeddelelse

Den 4. marts 2024 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 13 af 1. marts 2024. I henhold til programmet vil Schouw & Co. i perioden fra 4. marts 2024 til 31. december 2024 købe egne aktier for et maksimalt beløb på 200 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 26/4 2024 79.600 526,89 41.940.547 mandag 29. april 2024 1.900 529,73 1.006.487 tirsdag 30. april 2024 1.000 539,39 539.390 onsdag 1. maj 2024 1.000 555,04 555.040 torsdag 2. maj 2024 1.000 556,37 556.370 fredag 3. maj 2024 1.200 556,39 667.668 I perioden 29/4 2024 - 3/5 2024 6.100 545,07 3.324.955 Samlet i perioden 4/3 2024 - 3/5 2024 85.700 528,19 45.265.502 Ved periodens udløb ejer Schouw & Co. 2.19

Schouw & Co. share buy-back programme, week 18 20246.5.2024 15:11:08 CEST | Press release

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 26/4/2024 79,600 526.89 41,940,547 Monday, 29 April 2024 1,900 529.73 1,006,487 Tuesday, 30 April 2024 1,000 539.39 539,390 Wednesday, 1 May 2024 1,000 555.04 555,040 Thursday, 2 May 2024 1,000 556.37 556,370 Friday, 3 May 2024 1,200 556.39 667,668 In the period 29/4/2024 - 3/5/2024 6,100 545.07 3,324,955 Accumulated 4/3/2024 - 3/5/2024 85,700 528.19 45,265,502 Following the above transactions Schouw & Co. holds a

AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release

As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse

Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør

HiddenA line styled icon from Orion Icon Library.Eye